News
27 March 2025
PRESS RELEASE Gedea Biotech Receives US Patent for Preventing Preterm Birth
Gedea Biotech announced today that the United States Patent and Trademark Office (USPTO) has granted the company’s…
8 March 2025
Closing the Health Gap
On the Iternational Women's Day we want to address the THE WOMEN’S HEALTH GAP
3 December 2024
Gedea wins prestigious scale up award
On Thursday November 28th, at the Nordic Mentor Network For Entrepreneurship - NOME annual meeting in Copenhagen, we…
3 December 2024
Emilia, industrial doctoral student at Gedea and Karolinska Institutet
Emilia Lahtinen is an industrial Ph.D. student at Gedea and at Karolinska Institutet. Her project has the title…
3 December 2024
Anna-Karin Areskog strengthens the team
Gedea has recently strengthened its team by hiring Anna-Karin Areskog as QA Director. Anna-Karin has been a consultant…
6 November 2024
Gedea´s share issue oversubscribed by 54%
Gedea Biotech AB carried out a rights issue of SEK 24.3 million during October. The interest from both existing owners…
25 April 2024
Per-Ola Forsberg new CFO at Gedea
We are pleased to announce that Per-Ola Forsberg has been appointed as the new CFO of Gedea since April 20th. Per-Ola…
29 February 2024
Gedea Biotech selected for prestigious grant funding from the European Innovation Council, EIC
Yesterday, the EIC announced that Gedea Biotech has been selected for the €2.5M EIC Accelerator grant for the continued…
Convincing efficacy and safety results
pHyph has shown rapid symptom relief and long-term effects in clinical studies. Already on the first day of treatment, many patients experience a relief in unpleasant odor, and by day 7, it has completely disappeared in 60-70% of the patients. Treatment with pHyph shows a significantly better cure rate than the control group, and at day 35, 100% of the patients are still free from BV.
Rapid symptom relief
pHyph shows rapid effect, and by day 7, 80-90% experience noticeable symptom relief.
Day 7
At day 7, 60-70% of patients report absence of fishy smell.
Low recurrance rate
100 % of cured patients are still free from BV on day 35.

Gedea Biotech aims to make a sustainable contribution to global women’s health and to limit the unnecessary use of antibiotics. We develop a treatment that is safe to use, effective and free of antibiotics, to solve the problem with vaginal infections and their complications.
Annette Säfholm, CEO
annette.safholm@gedeabiotech.com
+46 (0) 708 - 91 86 81

According to the World Health Organization (WHO), antibiotic resistance is one of the greatest threats to global health of our time. A total of nearly 3% of all antibiotics prescribed to women in Sweden are used to treat bacterial vaginosis.*
*) Socialstyrelsen’s (the Swedish National Board of Health and Welfare) pharmaceutical database 2019.